NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
The notice of meeting, including the agenda, the draft detailed resolutions, and the principal details for attending and voting at this Ordinary and Extraordinary Annual Meeting of Shareholders were published in the French official bulletin of legal notices, the Bulletin des Annonces Légales Obligatoires (BALO), on
The documents and information concerning this shareholders’ meeting are available to shareholders as provided by applicable law and regulations on the Company's website at https://ir.nanobiotix.com/annual-general-meetings, at the Company’s registered office, or upon request via email at investors@nanobiotix.com.
Shareholders are kindly advised to consult the Company's website on a regular basis, as it could be updated to specify the final terms and modalities of participation in this shareholders’ meeting in accordance with sanitary, legal, or regulatory requirements.
2022 Financial Agenda
-
June 23, 2022 – Annual General Meeting,Paris, France -
September 28, 2022 – 2022 Half-Year Corporate and Financial Update -
November 9, 2022 – Third Quarter 2022 Corporate and Financial Update
About NBTXR3
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA,
About
For more information about
_______________________
1 For the purposes of specificity, the agenda published on the Company’s website includes an added draft resolution(n°37), which will be reflected in the updated agenda to be published in the BALO by
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005859/en/
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com
Media Relations
FR – Ulysse Communication
+33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com
US – Porter Novelli
+1 (781) 985-5967
Caitlin.hunt@porternovelli.com
Source: